The Italian Spallanzani Institute, the main infectious disease research institution in that country, reported this Thursday on the high efficacy of the Russian Spuntik V vaccine against the Omicron variant of Covid-19, above Pfizer and according to a comparative study between both drugs.
Putin ensures protection of Sputnik V against Omicron variant
Details a statement issued after the investigation carried out jointly between Italian specialists and Russian counterparts from the Gamaleya National Research Center for Epidemiology and Microbiology that Sputnik V “generates more than twice as many antibodies against the Omicron variant as two doses of the Pfizer vaccine”.
This is 2.1 times more in total, and 2.6 times more three months after vaccination,” details the document, which also revealed that under equal conditions with high levels of antibodies generated by both vaccines, 100 percent of those immunized with Sputnik V neutralized Omicron, compared to 83.3 percent of those vaccinated with Pfizer.
Meanwhile, in tests applied with sera, 74.2 percentage points of the samples vaccinated with Sputnik V neutralized said strain; by 56.9 of those who received Pfizer.
In this regard, the executive director of the Russian Direct Investment Fund (RDIF), Kirill Dmitriev, described the investigation as “very important, not only for Russia, but for the whole world.”
Who added that the Russian vaccine also helps prevent “the serious course of the disease”; He added that “we hope that the pandemic is coming to an end and having an effective vaccine like Sputnik is clearly an essential element to protect human lives.”
5/5 According to data from the Spallanzani Inst. and the results of other studies, the combined booster with Sputnik Light is the best solution to increase the efficacy of other vaccines and extend the period of protection against #Omicron https://t.co/wPIgjYH3tE
— Sputnik V (@sputnikvaccine)
January 20, 2022
In a report presented by the RDIF, the positive results of the “mix & match” trials of combinations of the single-dose Russian vaccine Sputnik Light with drugs produced by AstraZeneca, Sinopharm, Moderna and Cansino, developed in Argentina, were also avoided.
“The Sputnik Light booster has proven to be one of the best solutions for prolonging the period of protection of other vaccines. The Sputnik team urges immediate, open-label, global comparative studies on Sputnik Light and other vaccine boosters against the Covid,” said the RDIF in its report.
Sputnik V, a two-dose Russian anticovid drug, has been authorized in 71 countries, which include more than 4,000 million people; while Sputnik Light has the approval of 30 countries; and is recommended as an effective booster dose.